Gram-positive resistance: Pathogens, implications, and treatment options - Insights from the Society of Infectious Diseases Pharmacists

被引：28

作者：

Akins, RL ^{[1
]}

Haase, KK ^{[1
]}

机构：

[1] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharm Practice, Amarillo, TX 79106 USA

来源：

PHARMACOTHERAPY | 2005年 / 25卷 / 07期

关键词：

gram-positive bacteria; resistance; treatment decisions;

D O I：

10.1592/phco.2005.25.7.1001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Despite the advent of new antibiotics, resistance in gram-positive pathogens, including staphylococci and enterococci, continues to increase. This is evident with the recent emergence of vancomycin-resistant Staphylococcus aureus. Newer treatment agents are available, including quinupristin-dalfopristin, linezolid, and daptomycin. In addition, investigational agents are being explored. Clinical trials have been conducted for various infections, such as skin and skin structure infections, pneumonia, and bloodstream infections. Antibacterial activity, site of infection, and potential for adverse effects must be taken into account when making decisions regarding therapy Key Words: gram-positive bacteria, resistance, treatment decisions.

引用

页码：1001 / 1010

页数：10

共 88 条

[61] Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus [J].

Rand, KH ;

Houck, HJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) :2871-2875

[62] Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci [J].

Rand, KH ;

Houck, H .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (03) :530-532

[63]

RAND KH, 2002, 40 ANN M INF DIS SOC, P49

[64] Similar Hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections [J].

Rao, N ;

Ziran, BH ;

Wagener, MM ;

Santa, ER ;

Yu, VL .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (08) :1058-1064

[65] Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study [J].

Rubinstein, E ;

Cammarata, SK ;

Oliphant, TH ;

Wunderink, RG .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :402-412

[66] Community-acquired methicillin-resistant Staphylococcus aureus, Finland [J].

Salmenlinna, S ;

Lyytikäinen, O ;

Vuopio-Varkila, J .

EMERGING INFECTIOUS DISEASES, 2002, 8 (06) :602-607

[67] EMERGENCE OF VANCOMYCIN RESISTANCE IN COAGULASE-NEGATIVE STAPHYLOCOCCI [J].

SCHWALBE, RS ;

STAPLETON, JT ;

GILLIGAN, PH .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (15) :927-931

[68] Novel antibacterial agents for skin and skin structure infections [J].

Schweiger, ES ;

Weinberg, JM .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) :331-342

[69] Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus [J].

Sieradzki, R ;

Pinho, MG ;

Tomasz, A .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (27) :18942-18946

[70]

Solomon S, 2003, AM J INFECT CONTROL, V31, P481

← 1 2 3 4 5 6 7 8 9 →